secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2023-10-16T23:59:59+00:00
Accession:  0001640334-23-001846
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria grants exclusive global license to SulfoSyn for DehydraTECH-sulforaphane non-pharmaceutical products
--------------------------------------------------------------------------------

- Up-front cash payment received; minimum future payments and ongoing royalties agreed.
- Lexaria contracted for manufacturing at US partner facility for initial 2-year term.
- DehydraTECH applied to sulforaphane, a compound with anti-inflammatory and antioxidant properties.
- Non-pharmaceutical uses include supplements, additives, foods, and dietary ingredients.
- SulfoSyn granted sub-licensing rights for the licensed technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033423001846/0001640334-23-001846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033423001846/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-23-001846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer